16350-59-7

Usage

Uses

Used in Pharmaceutical Industry:
5-(methylsulfanyl)pyrimidine-2,4(1H,3H)-dione is used as an active pharmaceutical ingredient for the development of new drugs. Its unique structure and properties may contribute to the discovery of novel therapeutic agents with improved efficacy and selectivity.
Used in Organic Synthesis:
5-(methylsulfanyl)pyrimidine-2,4(1H,3H)-dione serves as a key intermediate in the synthesis of various organic compounds. Its versatile chemical reactivity allows for the preparation of a wide range of derivatives with potential applications in different fields.
Used in Medicinal Chemistry Research:
5-(methylsulfanyl)pyrimidine-2,4(1H,3H)-dione is utilized as a research tool in medicinal chemistry to study the structure-activity relationships of biologically active molecules. Its unique features can provide insights into the design of new drugs with improved pharmacological properties.
Used as a Mutagen in Genetic Studies:
5-(methylsulfanyl)pyrimidine-2,4(1H,3H)-dione is employed as a mutagen to induce mutations in various organisms. This allows researchers to study the effects of genetic alterations on biological processes and develop a better understanding of the molecular mechanisms underlying different diseases and conditions.

Upstream product

• 2949-92-0 methanethiosulfonic acid S-methyl ester 
• 696-07-1 5-iodouracil 
• 51-20-7 5-bromouracil 
• 5188-07-8 sodium thiomethoxide 
• 14020-53-2 5-mercapto uracil 
• 74-88-4 methyl iodide 

Downstream Products

• 29979-89-3 1-(2',3',5'-tri-O-benzoyl-β-D-ribofuranosyl)-5-(methylthio)uracil 
• 514842-56-9 2,4-dichloro-5-(methylsulfonyl)pyrimidine 
• 7401-98-1 2,4-dichloro-5-methylsulfanylpyrimidine 
• 1313720-30-7 4-(5-(methylthio)-4-morpholinopyrimidin-2-yl)benzenamine 
• 1313720-33-0 1-(4-(5-(methylthio)-4-morpholinopyrimidin-2-yl)phenyl)-3-phenylurea 
• 1313720-37-4 phenyl 4-(5-(methylthio)-4-morpholinopyrimidin-2-yl)phenylcarbamate 
• 1313720-52-3 1-(2-aminophenyl)-3-(4-(5-(methylthio)-4-morpholinopyrimidin-2-yl)phenyl)thiourea 
• 1313720-54-5 N-(4-(5-(methylthio)-4-morpholinopyrimidin-2-yl)phenyl)-1H-benzo[d]imidazol-2-amine 
• 1313720-69-2 phenyl 4-(5-(methylsulfinyl)-4-morpholinopyrimidin-2-yl)phenylcarbamate 

Relevant academic research and scientific papers

As tyrosine kinase inhibitors of the nitrogen-containing heteroaromatic ring derivatives

The present invention relates to compounds as represented by general formula (I) as tyrosine kinase inhibitors, preparation method thereof, pharmaceutical compositions containing the compounds, and uses thereof for preventing and/or treating instances of B-cell related leukemia, inflammatory diseases and autoimmune diseases, wherein A, ring B, L1, L2, R1, R2, R3, a, b, c, d, e, p and q are as defined in the specification.

MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX

Monocyclic pyrimidine and pyridine compounds having a benzyl amine substituent at the 4 position and a 5:6 bicyclic heteroaryl substituent at the 2 position of the pyrimidine or pyridine ring as well as optional aliphatic, functional and/or aromatic components substituted at other positions of the ring are disclosed. These compounds are inhibitors of the AAA proteasome complex containing p97 and are effective medicinal agents for treatment of diseases associated with p97 bioactivity such as cancer.

Synthesis and structure-activity relationship studies of N -benzyl-2-phenylpyrimidin-4-amine derivatives as potent usp1/uaf1 deubiquitinase inhibitors with anticancer activity against nonsmall cell lung cancer

Deregulation of ubiquitin conjugation or deconjugation has been implicated in the pathogenesis of many human diseases including cancer. The deubiquitinating enzyme USP1 (ubiquitin-specific protease 1), in association with UAF1 (USP1-associated factor 1), is a known regulator of DNA damage response and has been shown as a promising anticancer target. To further evaluate USP1/UAF1 as a therapeutic target, we conducted a quantitative high throughput screen of >400000 compounds and subsequent medicinal chemistry optimization of small molecules that inhibit the deubiquitinating activity of USP1/UAF1. Ultimately, these efforts led to the identification of ML323 (70) and related N-benzyl-2-phenylpyrimidin-4-amine derivatives, which possess nanomolar USP1/UAF1 inhibitory potency. Moreover, we demonstrate a strong correlation between compound IC50 values for USP1/UAF1 inhibition and activity in nonsmall cell lung cancer cells, specifically increased monoubiquitinated PCNA (Ub-PCNA) levels and decreased cell survival. Our results establish the druggability of the USP1/UAF1 deubiquitinase complex and its potential as a molecular target for anticancer therapies.

NOVEL PYRIMIDINE COMPOUNDS AS MTOR AND P13K INHIBITORS

The present invention relates to pyrimidine compounds of formula (I): which are useful in treating mTOR kinase- or PI3K kinase-related diseases.

Functionalization of unprotected uracil derivatives using the halogen - Magnesium exchange

The reaction of commercially available 5-iodouracil with 2 equiv of MeMgCl in the presence of LiCl, followed by the addition of i-PrMgCl-LiCl, provides the corresponding trimagnesiated species, which reacts with various electrophiles to give selectively 5

Pyrimidine derivatives

The present invention relates to trisubstituted pyrimidines of formula (I) 1wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterised by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.